PYRAZINO[1,2-A]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS
申请人:ESTEVE PHARMACEUTICALS, S.A.
公开号:EP2989104B1
公开(公告)日:2019-08-21
TRICYCLIC COMPOUNDS FOR USE IN TREATMENT OF PROLIFERATIVE DISORDERS.
申请人:Argonaut Therapeutics Limited
公开号:EP3596073B1
公开(公告)日:2022-05-11
TRICYCLIC COMPOUNDS FOR USE IN TREATMENT OF PROLIFERATIVE DISORDERS
申请人:ARGONAUT THERAPEUTICS LIMITED
公开号:US20200325132A1
公开(公告)日:2020-10-15
The present invention relates to compounds of Formula (I) as defined herein, and salts, hydrates and solvates thereof. The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to the use of compounds of Formula (I) in the treatment or prevention of PRMT5-mediated disorders, such as cancer.
Ruthenium catalyzed β-C(sp<sup>3</sup>)–H functionalization on the ‘privileged’ piperazine nucleus
作者:V. Murugesh、Christian Bruneau、Mathieu Achard、Apurba Ranjan Sahoo、Gangavaram V. M. Sharma、Surisetti Suresh
DOI:10.1039/c7cc05604d
日期:——
β-C(sp3)–H functionalization on the ‘privileged’ piperazine nucleus has been disclosed using ruthenium catalysis. The ruthenium catalyzed synthesis of a variety of piperazine fused indoles from ortho-piperazinyl (hetero)aryl aldehydes is presented. This transformation takes place via the dehydrogenation of piperazine followed by an intramolecular nucleophilic addition of the transient enamine moiety